secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oruka Therapeutics, Inc. (ORKA)
CIK:        0000907654
Form:       8-K
Filed at:   2024-02-01T23:59:59+00:00
Accession:  0000950170-24-009852
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ARCA biopharma posts 2023 net loss of $5.3M ($0.37/share); cash $37.4M
----------------------------------------------------------------------

- Net loss improved to $5.3M from $9.9M in 2022; basic EPS loss $0.37 vs $0.69.
- Cash and equivalents $37.4M at Dec 31, 2023, down from $42.4M; runway through mid-2025.
- G&A expenses rose to $6.3M (2023) from $5.8M (2022) on higher professional and strategic review fees.
- R&D expenses fell to $1.0M from $4.7M due to lower clinical costs and headcount reduction.
- Strategic review ongoing with no defined timeline; potential merger, asset sale, or other alternatives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/907654/000095017024009852/0000950170-24-009852-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/907654/000095017024009852/abio-20240201.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-009852

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer